Aclarion, Inc. ACON 深 沪
已收盘 02-06 16:00:00 美东时间
2.75
+0.390
+16.53%
华盛通- 最 高2.815
- 今 开2.43
- 成交量 18.56万股
- 最 低 2.41
- 昨 收 2.36
- 总市值 289.95万
- 52周最高 229.50
- 市盈率 静 --
- 换手率 17.60%
- 52周最低 2.3401
- 委 比 -63.35%
- 总股本 105.44万
- 历史最高 586116.00
- 量 比 0.86
- 振 幅 17.16%
- 历史最低 2.3401
- 每 手 1
- 风险率 35.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout
Aclarion, Inc. (NASDAQ: ACON) closed a $10.4 million financing at $5.18/share, boosting balance sheet & extending cash runway to 2028.
01-13 23:51
Aclarion Raises $10.4M, Extends Cash Runway Into 2028
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help
01-13 19:01
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers NovaBay Pharmaceuticals (AMEX:NBY) stock rose 36.9% to $12.95 during F...
01-10 01:05
Market-Moving News for January 8th
ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Accelerates ACRV: 38% | Acrivon Therapeutics Announces Update On ACR-368 Program, Reports Initial Clinical
01-08 20:35
Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Accelerates
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help
01-08 19:14
Aclarion Announces Publication Of Featured Article Tech Update In Upcoming Special Pain Issue Of The International Journal Of Spine Surgery
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine careIJSS publishes
2025-12-04 21:05
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
Ascendiant Capital Maintains Buy on Aclarion, Raises Price Target to $23
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the price target from $22 to $23.
2025-11-20 18:41
Aclarion Q3 EPS $(2.93) Misses $(2.62) Estimate, Sales $18.942K Miss $40.000K Estimate
Aclarion (NASDAQ:ACON) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.62) by 11.83 percent. This is a 99.8 percent increase over losses of $(1.50 thousand) per share
2025-11-12 21:52
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
Aclarion, Inc. reported strong financials, market adoption, and clinical trial progress in its Q3 2025 update. The company has a debt-free balance sheet with $13.3 million in cash, supporting commercial growth. Nociscan scan volumes increased 89% year-over-year, marking three consecutive quarters of record utilization across U.S., U.K., and E.U. markets. The CLARITY pivotal trial is advancing on schedule with early 3-month readouts expected in Q2...
2025-10-14 10:09
